US equities |
MU $1,045.56 ▲+0.00% INTC $112.50 ▲+0.00% NVDA $239.24 ▲+0.00% SNDK $1,660.46 ▲+0.00% SPCX $171.92 ▲+0.00% MRVL $287.01 ▲+0.00% AMD $649.42 ▲+0.00% MSTR $164.55 ▲+0.00%
FinancialContent

Metsera, Inc. - Common Stock (NQ:MTSR)

70.50 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Metsera, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day. 
Via Stocktwits
News headline image
Can AI Drive Peloton's Comeback? ↗
The market is hopping with interesting news. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Down 55%, Should You Buy the Dip on Pfizer? ↗
Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Pfizer Stock a Buy After This $10 Billion Acquisition? ↗
The company has been on an acquisition spree for years, and this one may be the most important yet. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
Dow Futures Rise As Senate Votes To End Government Shutdown: MTSR, VSAT, RUM, TSM Among Stocks To Watch ↗
Via Stocktwits
Topics Stocks
News headline image
Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market ↗
Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn. 
Via Benzinga
News headline image
Ozempic Maker Novo Nordisk Faces Board Shakeup ↗
Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market. 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Why Is Everyone Talking About Novo Nordisk Stock? ↗
There is hardly a dull moment for the drugmaker these days. 
Via The Motley Fool
News headline image
Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗
The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction. 
Via Stocktwits
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗
Via Stocktwits
News headline image
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report ↗
CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game. 
Via Stocktwits
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership. 
Via Benzinga
News headline image
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? ↗
Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Metsera's Share Price Is Plummeting This Week ↗
The biotech start-up's stock had been rising rapidly in 2025. 
Via The Motley Fool
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗
Via Stocktwits
News headline image
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India ↗
Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc. 
Via Benzinga
News headline image
Where Will Pfizer Be in 3 Years? ↗
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? ↗
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs. 
Via The Motley Fool
News headline image
Shutdown Deal Breathes New Life Into Wall Street ↗
The prospect of a quick end to the US government shutdown has rekindled investor confidence. Tech rebounds, semiconductors sprint ahead, and insurers feel political pressure building. Meanwhile, all... 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion ↗
The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Monday's pre-market session: top gainers and losers ↗
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗
Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks. 
Via Stocktwits
News headline image
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard." 
Via Benzinga
News headline image
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy ↗
 
Via Benzinga
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
< Previous 1 2 3 4 5 Next >